Ontology highlight
ABSTRACT: Background
Protection from severe disease and hospitalization by SARS-CoV-2 vaccination has been amply demonstrated by real-world data. However, the rapidly evolving pandemic raises new concerns. One pertains efficacy of adenoviral vector-based vaccines, particularly the single-dose Ad26.COV2.S, relative to mRNA vaccines.Main body
We investigated the immunogenicity of Ad26.COV2.S and mRNA vaccines in 33 subjects vaccinated with either vaccine class 5 months earlier on average. After controlling for the time since vaccination, Spike-binding antibody and neutralizing antibody levels were higher in the mRNA-vaccinated subjects, while no significant differences in antigen-specific B cell and T cell responses were observed between the two groups.Conclusions
A dichotomy exists between the humoral and cellular responses elicited by the two vaccine classes. Testing only for humoral responses to compare the durability of SARS-CoV-2 vaccine-induced responses, as typically performed for public health and research purposes, is insufficient.
SUBMITTER: Ukey R
PROVIDER: S-EPMC8786593 | biostudies-literature | 2022 Jan
REPOSITORIES: biostudies-literature
Ukey Rahul R Bruiners Natalie N Mishra Hridesh H Mishra Pankaj K PK McCloskey Deborah D Onyuka Alberta A Chen Fei F Pinter Abraham A Weiskopf Daniela D Sette Alessandro A Roy Jason J Gaur Sunanda S Gennaro Maria Laura ML
BMC medicine 20220125 1
<h4>Background</h4>Protection from severe disease and hospitalization by SARS-CoV-2 vaccination has been amply demonstrated by real-world data. However, the rapidly evolving pandemic raises new concerns. One pertains efficacy of adenoviral vector-based vaccines, particularly the single-dose Ad26.COV2.S, relative to mRNA vaccines.<h4>Main body</h4>We investigated the immunogenicity of Ad26.COV2.S and mRNA vaccines in 33 subjects vaccinated with either vaccine class 5 months earlier on average. Af ...[more]